• Panagiotis Akritopoulos, Paraskevi Papaioannidou, Ippokratis Hatzokos, Afroditi Haritanti, Eirini Iosifidou, Maria Kotoula, and Vassiliki Mirtsou-Fidani.
• Department of Pharmacology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
• Arch Orthop Trauma Surg. 2009 Oct 1; 129 (10): 142714321427-32.

IntroductionSelective and non-selective cyclo-oxygenase (COX) inhibitors impair bone healing by inhibiting prostaglandin synthesis. The purpose of this study was to evaluate the long-term effect of parecoxib, a selective COX-2 inhibitor, on bone healing in rats, when it is applied in a pattern similar to clinical treatment patterns, that is, in a high dose and for a short period after bone fracture.MethodClosed non-displaced mid-diaphyseal fractures in the middle of the left femoral shaft were generated in each animal. In the study group, parecoxib sodium (1.06 mg/kg) was administered intra-peritoneally every day for 7 days. In the control group, normal saline was administered intra-peritoneally every day for 7 days. In both groups fracture healing (bone union and callus formation) was evaluated with X-rays 28 and 42 days after surgery.ResultsBone healing was lower in the study group (60 vs. 80% in the control group 28 days after fracture and 80 vs. 90% 42 days after fracture) but this difference was not statistically significant (P > 0.05).ConclusionParecoxib does not have a significant long-term effect on bone healing in rats, when it is administered in a high dose and for a short period after bone fracture.

16 keywords...

hide…